Retinol-binding protein 4 and cytokeratin 18 are two newly discovered markers associated with nonalcoholic fatty liver disease
[1]Berggard I.Studies on the plasma protein in normal human urine[J].Clinica Chimica Acta, 1961, 6 (3) :413-429.
|
[2]陈健, 周度金.视黄醇类结合蛋白的分类、结构及功能[J].生命的化学, 2004, 24 (2) :112-115.
|
[3]Rocchi M, Covone A, Romeo G, et al.Regional mapping of RBP4to10q23-q24and RBP1to3q21-q22in man[J].Somat Cell Mol, 1989, 15 (2) :185-190.
|
[4]Flower DR, North AC, SansomCE.The lipoealin protein family:struc-turaland sequence overview[J].Biochim Biophys Aeta, 2000, 1482 (1-2) :9-24.
|
[5]Stefano J, Keith G, Graham J, et al.Charaterization of two post trans-lationally processed forms of human serum retinol-bindind protein:altered ratios in chronic renalfailure[J].J Lipid Research, 1995, 36 (5) :1817-1818.
|
[6]Guo XH, Chu MX, Zhou ZX.Molecular biology of the retinol-bind-ing proteins and their genes[J].Yi Chuan, 2004, 26 (2) :257-262.
|
[7]Yang Q, Graham TE, Mody N, et al.Serum retinol bindingprotein4cont ributes to insulin resistance in obesity and type2diabetes[J].Nature, 2005, 436 (7049) :356-362.
|
[8]Seo J A, Kim NH, Park S Y, et al.Serum retinol-binding protein4levels are elevated in non-alcoholic fatty liver disease[J].Clini-cal Endocrinology, 2008, 68 (4) :555-560.
|
[9]Huang J F, Dai C Y, Yu ML, et al.Serumretinol-binding protein4is inversely correlated with disease severity of chronic hepatitis C[J].J Hepatology, 2009, 50 (3) :471-478.
|
[10]Seo JA, Kim NH, Park SY, et al.Serum retinol-binding protein4levels are elevated inon2alcoholicfattyliverdisease[J].Clinical Endo-crinology, 2008, 68 (4) :55-560.
|
[11]Graham TE, Yang Q, Bluher M, et al.Retinol-binding protein4and insulin resistance in lean, obese, and diabetic subject[J].NEn-gl J Med, 2006, 354 (24) :2552-2563.
|
[12]Wu H, Jia W, Bao Y, et al.Serum retinol binding protein4and nonalcoholic fat ty liver disease in patient s wit h type2diabetesmell-itus[J].Diabetes Res Clin Pract, 2008, 79 (2) :185-190.
|
[13]Yan K K, Palmer C S, Lloyd A R, et al.Relationship of Retinol Binding Protein-4with Liver Injury in Morbidly Obese Subjects[J].Hepatology, 2009, 50 (4) :S789A.
|
[14]Barak V, Goike H, Panaretakis KW, et al.Clinical Utility of cytok-eratins as tumor markers[J].ClinBiochera, 2004, 37 (7) :1529-1540.
|
[15]Linder S, Havelka AM, Ueno T, et a1.Determiningtumor apoptosis and necrosis in patient serumusingcytokeratin18as a biomarker[J].Cancer Lett, 2004, 24 (1) :1-9.
|
[16]Petta S, Camma C, Marco V D, et al.High Level RBP4Expres-sion is Associated with the Severity of Fibrosis in NAFLD Patients[J].Hepatology, 2009, 50 (4) :S800A.
|
[17]Yagmur E, Weiskirchen R, Gressner AM, et al.Insulin Resistance in Liver Cirrhosis Is Not Associated With Circulating Retinol-Bind-ing Protein4[J].Diabetes Care, 2007, 30 (5) :1168-1172.
|
[18]Tacke F, Weiskirchen R, Trautwein C, et al.Liver Function Criti-cally Determines Serum Retinol-Binding Protein4 (RBP4) Levels in Patients with Chronic Liver Disease and Cirrhosis[J].Hepotolo-gy.2008, 48 (1) :28-37.
|
[19]Zatioukal K, Stumptner C, Fuchsbichler A, et al.The keratin cy-toskeleton in liver diseases[J].Pathol, 2004, 4 (4) :367-376.
|
[20]Gilbert S, Lorange A, Daigle N, et al.Simple epithelium keratins8and18provide resistance to Fas-mediated apoptosis.The protection occurs through a receptor-targeting modulation[J].J CellBiol, 2001, 154 (4) :763-773.
|
[21]李娟, 石英, 武聚山, 等.角蛋白K18及其33、52位丝氨酸磷酸化在HBV感染肝脏疾病中的表达及意义[J].临床肝胆病杂志, 2008, 24 (4) :213-214.
|
[22]Gonzalez-Quintela A, Garcia J, Campos J.Serum cytokeratins in alcoholic liver disease:contrasting levels of cytokeratin-18and cy-tokeratin-19[J].Alcohol, 2006, 38 (1) :45-49.
|
[23]Prati D, Taioli E, Zanella A, et al.Updated definitions of healthy ranges for serum alanine aminotransferase levels[J].Annal Intern Med, 2002, 137 (1) :1-10.
|
[24]Malik R, Chang M, Bhaskar K, et al.The clinical utility of biomark-ers and the nonalcoholic steatohepatitis CRNliver biopsy scoring sys-tem in patients with nonalcoholic fatty liver disease[J].J Gastroen-terol Hepatol, 2009, 24 (4) :564-568.
|
[25]Diab DL, Yerian L, Schauer P, et al.Cytokeratin18Fragment Levels as a Noninvasive Biomarker for Nonalcoholic Steatohepatitis in Bariatric Surgery Patients[J].Clinical Gastroenterology and Hep-atology, 2008, 6 (11) :1249-1254.
|
[26]Diab D, Yerian L, Schauer P, et al.Cytokeratin18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease[J].J Pediatr Gastroenterol Nutr, 2008, 47 (4) :481-485.
|
[27]Gonzalez-Quintela A, Mallo N, Mella C, et al.Serum levels of cy-tokeratin-18 (tissuepolypeptide-specific antigen) in liver diseases[J].Liver International, 2006, 26 (10) :1217-1224.
|
[1] | Xue MiaoMiao, Li XuePing, Li Ya, Yan NaNa, Xu GangZhu, Song Mei. Research advances in sodium-glucose co-transporter 2 inhibitor in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(12): 2812-2816. doi: 10.3969/j.issn.1001-5256.2019.12.037 |
[2] | Xi LiTing, Zhang HuiXian, Wu AiRong, Xu ChunFang, Zhu JinZhou. Value of combined measurement of serum alpha-fetoprotein, Dickkopf-1, and cytoskeleton-associated protein 4 in diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(6): 1276-1279. doi: 10.3969/j.issn.1001-5256.2019.06.019 |
[6] | Guo YinYan, Li Peng. A study on the role of serum Retinol Binding Protein 4 in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(4): 279-280+301. |
[7] | Li LiangPing, Zhong Huang. The study of cytokeratin 18 fragments and inflammation related factors in non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 359-363. |
[8] | Ma LiNa, Feng Ming, Zhou YingZhi, Ma Jia, Hao Peng. The relationship between nonalcoholic fatty liver disease and insulin resistance[J]. Journal of Clinical Hepatology, 2010, 26(2): 173-174+177. |
[9] | Huang WeiShen, Wang Wei. Basic management of nonalcoholic fatty liver disease [J]. Journal of Clinical Hepatology, 2010, 26(2): 156-159. |
[11] | Li Juan, Shi Ying, Wu JuShan, Sheng Bo, Yu HongWei, Wu Hao, Chen XinYue, Chen DeXi. The expression of Keratin 18 and its Ser33、Ser52 phosphorylation level changes in HBV infected liver disease and significance[J]. Journal of Clinical Hepatology, 2008, 24(4): 243-245. |
[12] | Xiang Yang, Ye JiaRun, Li XinPing. Safety and effectiveness of pioglitazone in the treatment of non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2007, 23(6): 434-435. |
[13] | Liang Bing, Chen Xi, Liu ShuangYan, Wang YiGe, An QiuHong. The relationship between non-alcoholic fatty liver disease and insulin resistance[J]. Journal of Clinical Hepatology, 2006, 22(3): 213-214. |
[14] | Lu ZhenYa, Wang QunYan, Rao WeiQiang, Cai WeiMin. Relationship between leptin resistance and nonalcoholic fatty liver in male patients.[J]. Journal of Clinical Hepatology, 2006, 22(1): 39-41. |
[19] | Ma YingJie, Fang LiFeng, Feng SuPing, Jia KeLi, Fu ZhenLie. Obesity and insulin resistance in nonalcoholic fatty liver[J]. Journal of Clinical Hepatology, 2002, 18(4): 241-242. |